SEARCH

SEARCH BY CITATION

References

  • Apple, R. J., Erlich, H. A., Klitz, W., Manos, M. M., Becker, T. M. and Wheeler, C. M., HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature (Genet.), 6, 157162 (1994).
  • Baay, M. F. D., Duk, J. M., Burger, M. P. M., Debruijn, H. W. A., Stolz, E. and Herbrink, P., Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma. J. med. Virol., 45, 342347 (1995).
  • Brière, F., Servet-Delprat, C., Bridon, J.-M., Saint-Remy, J.-M. and Banchereau, J., Human Interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J. exp. Med., 179, 757762 (1994).
  • De Gruul, T. D., Bontkes, H. J., Stukart, M. J., Walboomers, J. M. M., Remmink, A. J., Verheijen, R. H. M., Helmerhorst, Th., J. M., Meijer, C. J. L. M., and Scheper, R. J., T-cell proliferative responses against the human papillomavirus type-16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. gen. Virol., 77, 21832191 (1996).
  • Dillner, J., Disappearance of antibodies to HPV-16 E7 after treatment for cervical cancer. Lancet, 341, 1594 (1993).
  • Duggan-Keen, M., Keating, P. J., Cromme, F. V., Walboomers, J. M. M. and Stern, P. L., Alterations in major histocompatibility complex expression in cervical cancer: possible consequences for immunotherapy. Papillomavirus Rep., 5, 39 (1994).
  • Gissmann, L. and Müller, M., Serological immune responses to HPV. In: P. L.Stern and M. A.Stanley (eds.), Human papillomaviruses and cervical cancer; biology and immunology, pp. 132145, Oxford Medical Publications, Oxford, New York, Tokyo (1994).
  • Hamsikova, E., Novak, J., Hofmannova, V., Muñoz, N., Bosch, F. X., Desanjose, S., Shah, K., Roth, Z. and Vonka, V., Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J. infect. Dis., 170, 14241431 (1994).
  • IARC, Monographs on the evaluation of carcinogenic risks to humans. Vol. 64, The Human Papillomavirus, IARC, Lyon (1995).
  • Inoue, R., Kondo, N., Kobayashi, Y., Fukutomi, O. and Orii, T., IgG2 deficiency associated with defects in production of interferon-gamma; comparison with common variable immunodeficiency. Scand. J. Immunol., 41, 130134 (1995).
  • Kawano, Y., Noma, T. and Yata, J., Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of human IgG2. J. Immunol., 153, 49484958 (1995).
  • Krchnak, V., Vagner, J., Suchankova, A., Krcmar, M., Ritterova, L. and Vonka, V., Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J. gen. Virol., 71, 27192724 (1990).
  • Müller, M., Viscidi, R. P., Sun, Y., Guerrero, E., Hill, P. M., Shah, F., Bosch, F. X., Muñoz, N., Gissmann, L. and Shah, K., Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology, 187, 508514 (1992).
  • Müller, M., Viscidi, R. P., Ulken, V., Bavinck, J. N. B., Hill, P. M., Fisher, S. G., Reid, R., Muñoz, N., Schneider, A., Shah, K. V. and Gissmann, L., Antibodies to the E4, E6, and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated diseases and in the normal population. J. invest. Dermatol., 104, 138141 (1995).
  • Nindl, I., Benitezbribiesca, L., Berumen, J., Farmanara, N., Fisher, S., Gross, G., Lopezcarillo, L., Muller, M., Tommasino, M., Vazquezcuriel, A. and Gissmann, L., Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoprotens in sera of cervical cancer patients. Arch. Virol., 137, 341353 (1994).
  • Remmink, A. J., Walboomers, J. M. M., Helmerhorst, Th. J. M., Voor-Horst, F. J., Rozendaal, L., Risse, E. K. J., Meijer, C. J. L. M., and Kenemans, P., The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer, 61, 306311 (1995).
  • Schafer, A., Friemann, W., Mielke, M., Schwatlander, B. and Koch, M. A., The increased frequency of cervical dysplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Amer. J. Obstet. Gynecol., 164, 593599 (1991).
  • Schiller, J. T. and Roden, R. B. S., Papillomavirus-like particles. Papillomavirus Rep., 6, 121128 (1995).
  • Spiegelberg, H. L., Beck, L., Kocher, H. P., Fanslow, W. C. and Lucas, A. H., Role of Interleukin-4 in human Immunoglobulin E formation in hu-PBL-SCID mice. J. clin. Invest., 93, 711717 (1994).
  • Stanley, M. A., Virus-keratinocyte interactions in the infectious cycle. In: P. L.Stern and M. A.Stanley (eds.), Human papillomaviruses and cervical cancer; biology and immunology, pp. 116128, Oxford Medical Publications, Oxford, New York, Tokyo (1994).
  • Viscidi, R. P., Sun, Y., Tsuzaki, B., Bosch, F. X., Munñoz, N. and Shah, K. V., Serologic response in human papillomavirus-associated invasive cervical cancer. Int. J. Cancer, 55, 780784 (1993).